Nanotechnology in Drug Delievery system

Vinit Singh[1], Satyam Kumar[2], Aditya Mishra[3], Aditya Kumar[4]
[1,2,3,4] *College of Pharmacy Roorkee (Haridwar University)*

***Abstract*—Nanotechnology offers transformative capabilities in drug delivery systems by enabling the precise engineering of materials at the nanoscale, typically within the 1–100 nm range. This review explores recent advancements in nanocarrier technologies—including liposomes, dendrimers, polymeric nanoparticles, and quantum dots—that facilitate targeted, controlled, and sustained delivery of therapeutic agents. These nanosystems improve drug bioavailability, reduce systemic toxicity, and enable site-specific targeting, which is particularly beneficial in treating complex diseases such as cancer and neurodegenerative disorders. Surface functionalization with targeting ligands further enhances selectivity and therapeutic efficacy. Notably, nanomaterials such as chitosan, PLGA, and peptide-based nanotubes have been successfully employed for the delivery of anti-cancer drugs and RNAi therapeutics. The ability of nanoparticle systems to traverse biological barriers, such as the blood-brain barrier, underscores their potential in treating brain malignancies. Additionally, nanotechnologies targeting molecular pathways involving VEGF and cell adhesion molecules represent promising strategies for disease modulation. Despite these advances, challenges remain in terms of nanoparticle toxicity, biocompatibility, scalability, and regulatory approval. This review outlines key developments and identifies future directions where nanotechnology can address critical limitations in current drug delivery paradigms, positioning it as a vital tool in the evolution of precision medicine.**

***Index Terms*—Nanotechnology, Drug Delivery, Nanoscale, Liposomes, Quantum Dots, Bioavailability, PLGA, RNAi, VEGF & etc.**

I. INTRODUCTION

Nanotechnology has emerged as a transformative approach in the field of drug delivery, offering innovative solutions to long-standing challenges in therapeutic design and administration. Nanoparticles—typically less than 100 nanometers in at least one dimension—have gained prominence due to their ability to enhance drug solubility, improve pharmacokinetics, and achieve targeted delivery with reduced systemic toxicity. These nanoscale systems are often constructed from biodegradable materials such as polymers, lipids, and metals, enabling them to interact efficiently with biological systems and cross complex physiological barriers.

One of the key advantages of nanoparticle-based drug delivery systems lies in their versatility. Therapeutic agents can be encapsulated within the nanoparticle matrix or conjugated to their surfaces, allowing for controlled and sustained drug release. Furthermore, these nanocarriers can be engineered with targeting ligands that enable specific interaction with cell-surface receptors on diseased cells, enhancing cellular uptake and minimizing off-target effects. This precision delivery is particularly beneficial in the treatment of complex diseases such as cancer, where conventional therapies often exhibit limited efficacy and high toxicity.

The development of effective nanosystems requires a comprehensive understanding of their interactions within the biological environment, including recognition by immune cells, receptor-mediated uptake, intracellular trafficking, and mechanisms of drug release. Additionally, the success of these systems hinges on addressing barriers such as drug degradation, efflux by membrane transporters, and changes in cellular signaling pathways associated with disease progression.

Despite significant advances, several challenges remain, including the need for improved biocompatibility, long-term safety evaluation, and scalable manufacturing processes. Continued research is also essential to fully elucidate the molecular mechanisms governing nanoparticle-cell interactions and to optimize delivery strategies for personalized medicine.

This review aims to provide a comprehensive overview of the role of nanotechnology in drug delivery, focusing on the design and application of nanoscale carriers, their biological interactions,

therapeutic advantages, and current challenges. It further highlights the latest research developments and future directions toward the clinical translation of nanomedicine-based drug delivery systems.

Design of Nanoparticle-Based Drug Delivery Systems

The design of nanoparticle-based drug delivery systems is a multidisciplinary endeavor, integrating principles from chemistry, materials science, pharmacology, and molecular biology. The aim is to engineer nanoscale carriers capable of encapsulating therapeutic agents, protecting them from degradation, navigating the biological environment, and delivering them selectively to target sites. To achieve safe and effective delivery, several critical design parameters must be considered.

1. Material Selection

The material used to construct nanoparticles significantly influences their drug-carrying capacity, degradation rate, and compatibility with biological systems. Common classes of materials include:

Polymers (e.g., PLGA, PEG, chitosan): Biodegradable and modifiable for controlled drug release.

Lipids (e.g., liposomes, solid lipid nanoparticles): Suitable for encapsulating hydrophilic and hydrophobic drugs.

Metals/Metal oxides (e.g., gold, iron oxide): Provide imaging capability and targeted delivery, especially in theranostics.

Dendrimers/Nanogels: Possess highly branched structures allowing high drug-loading efficiency.

2. Particle Size and Surface Characteristics

Nanoparticle size and surface properties directly affect their distribution, circulation time, and cellular uptake:

Size (10–100 nm) facilitates passive targeting via the enhanced permeability and retention (EPR) effect and helps in avoiding rapid renal clearance.

Surface charge influences biodistribution—slightly negative or neutral particles tend to evade immune recognition.

Surface functionalization with polyethylene glycol (PEG) enhances circulation time, while ligand conjugation (e.g., antibodies, aptamers) allows for active targeting of specific cellular receptors.

3. Drug Loading and Release Mechanisms

Drugs may be physically entrapped, adsorbed onto, or covalently bound to nanoparticles. The design must enable:

Sustained release for prolonged therapeutic effect and reduced dosing frequency.

Stimuli-responsive release (e.g., triggered by pH, temperature, or enzymatic activity) for site-specific drug delivery within diseased tissues.

4. Targeting Strategies

Two primary strategies are employed to guide nanoparticles to their intended site of action:

Passive targeting utilizes the EPR effect in tumors or inflamed tissues where vasculature is more permeable.

Active targeting involves conjugation of ligands to nanoparticles, enabling selective binding to overexpressed receptors on target cells (e.g., folate, transferrin, HER2).

5. Stability and Biocompatibility

Ensuring that nanoparticles remain stable in biological fluids and do not elicit toxic or immunogenic responses is crucial. Strategies include:

PEGylation to reduce protein adsorption ("stealth effect").

Use of stabilizers and crosslinkers to enhance structural integrity.

Design for enzymatic resistance in physiological environments.

6. Scalability and Regulatory Considerations

Translating nanoparticle systems from lab to clinic requires scalable manufacturing, adherence to Good Manufacturing Practices (GMP), and compliance with regulatory standards. Batch consistency, sterilization methods, and long-term storage stability are essential considerations during development.

Nanoparticle-based systems have demonstrated success in improving the delivery of poorly soluble drugs, enhancing bioavailability, and enabling precise targeting to disease sites (Figure 1). For instance, drugs such as paclitaxel, doxorubicin, 5-fluorouracil, and dexamethasone have been successfully incorporated into nanoparticle formulations

A notable example is the encapsulation of dexamethasone—a glucocorticoid—using PLGA or PLA-based nanoparticles. This design enhances intracellular delivery, where dexamethasone binds to cytoplasmic receptors and modulates gene expression, leading to anti-proliferative effects. Sustained release from such formulations has been

shown to inhibit vascular smooth muscle cell proliferation.

FIGURE 1. TARGETED VS. UNTARGETED DRUG DELIVERY USING NANOPARTICLES



Targeting Cancer Cells with Nanoparticles

Cancer remains one of the most challenging diseases to treat, largely due to issues such as poor drug bioavailability, non-specific distribution, and the development of drug resistance. Nanoparticle-based drug delivery systems offer a promising strategy for overcoming these limitations by enabling site-specific targeting, controlled drug release, and improved intracellular delivery. Their ability to selectively target cancer cells while sparing healthy tissues marks a major advancement in oncology.

1. Mechanisms of Targeting

1.1 Passive Targeting

Passive targeting leverages the Enhanced Permeability and Retention (EPR) effect, a phenomenon in which nanoparticles accumulate preferentially in tumor tissues due to the leaky vasculature and impaired lymphatic drainage commonly found in tumors. Nanoparticles sized between 10–100 nm can extravasate into tumor interstitial space, enhancing local drug concentration without the need for active binding mechanisms.

1.2 Active Targeting

In active targeting, nanoparticles are engineered with ligands that recognize specific receptors overexpressed on cancer cells. These ligands include:

Monoclonal antibodies (e.g., trastuzumab for HER2-positive tumors)

Peptides (e.g., RGD for integrins)

Aptamers

Small molecules (e.g., folic acid for folate receptor-targeted delivery)

These functionalized nanoparticles undergo receptor-mediated endocytosis, ensuring drug release specifically within cancerous tissues. Active targeting is especially valuable in treating metastatic and

heterogeneous tumors with variable receptor expression.

2. Examples of Targeted Nanoparticle Systems

Several nanoparticle systems have demonstrated promising results in preclinical and clinical studies:

HER2-targeted liposomes loaded with doxorubicin have shown increased cytotoxicity in HER2-positive breast cancer cells while reducing off-target toxicity.

Folate-conjugated nanoparticles effectively target ovarian and breast cancers due to high expression of folate receptor-α.

Transferrin-modified nanoparticles facilitate drug delivery to rapidly dividing cancer cells by targeting transferrin receptors.

EGFR-targeted gold nanoparticles serve dual purposes as delivery agents and in photothermal therapy, representing a key step toward multifunctional theranostics.

3. Overcoming Multidrug Resistance (MDR)

Multidrug resistance remains a major barrier in chemotherapy, often caused by overexpression of efflux transporters such as P-glycoprotein (P-gp). Nanoparticles can overcome MDR through:

Direct intracellular delivery, bypassing P-gp recognition.

Co-delivery of P-gp inhibitors with chemotherapeutics.

Use of stimuli-responsive materials that release the drug in response to tumor-specific conditions (e.g., acidic pH, high glutathione levels).

Paclitaxel-loaded nanoparticles, for example, have demonstrated the ability to reverse resistance in HCT-15 colon cancer cells, enabling drug retention and enhanced cytotoxicity.

4. Targeting Brain Tumors

Brain cancers are especially difficult to diagnose and treat due to the presence of the blood-brain barrier (BBB), which restricts the entry of most therapeutic agents. Nanoparticles offer new hope by enabling drugs to cross the BBB via specialized targeting mechanisms.

- Apolipoprotein E (ApoE)-conjugated human serum albumin nanoparticles have been used to deliver drugs like loperamide, which typically cannot cross the BBB. When injected intravenously, this nanoparticle system enabled loperamide to induce antinociceptive effects in mice, indicating successful brain delivery.
- PEBBLE (Probes Encapsulated by Biologically Localized Embedding) nanoparticles are multifunctional polymer spheres developed by Kopelman and colleagues. These nanoparticles can simultaneously house:
  - Targeting ligands for tumor-specific recognition
  - Imaging agents for MRI-based diagnostics
  - Cytotoxic drugs for localized therapy

This design exemplifies the growing field of theranostics, where diagnosis and treatment are combined in a single nanosystem.

Polysorbate 80-coated nanoparticles carrying doxorubicin have been shown to cross the intact BBB and achieve therapeutic drug concentrations in the brain, demonstrating efficacy in preclinical models of brain tumors.

Superparamagnetic iron oxide nanoparticles conjugated with targeting ligands can be used for early and accurate localization of brain tumors via magnetic resonance imaging (MRI), greatly enhancing early detection and monitoring of therapeutic response.

Furthermore, folic acid-PEG-modified nanoparticles have demonstrated increased uptake in brain tumor cells, combining receptor-mediated targeting with stealth properties to evade immune detection and prolong systemic circulation.

5. Clinical Translation and Future Perspectives

FDA-approved nanomedicines such as Doxil (liposomal doxorubicin) and Abraxane (albumin-bound paclitaxel) have already validated the clinical potential of nanoparticle-based targeting. However, several challenges remain in the widespread clinical adoption of targeted nanoparticles:

- Heterogeneity of tumor markers across patient populations
- Immune clearance and opsonization
- Complex manufacturing and scale-up processes
- Long-term biocompatibility and toxicity concerns

Emerging technologies combining targeted delivery, imaging, and smart release mechanisms continue to push the frontier of cancer nanomedicine. Future success will depend on improved design strategies,

robust preclinical validation, and personalized approaches tailored to the molecular profile of individual tumors.

II. CONCLUSION

Nanotechnology has profoundly reshaped the landscape of drug delivery by offering innovative solutions to many of the challenges faced in conventional therapeutics, particularly in the treatment of complex diseases such as cancer and neurological disorders. Nanoparticle-based delivery systems, including liposomes, polymeric nanoparticles, dendrimers, and metallic nanostructures, have demonstrated enhanced drug bioavailability, reduced systemic toxicity, and precise site-specific targeting. These capabilities stem from their tunable physicochemical properties, the ability to encapsulate diverse therapeutic agents, and potential for functionalization with targeting ligands.

Significant progress has been made in the rational design of nanoparticle systems—from material selection and surface engineering to controlled drug release and active targeting mechanisms. The ability to exploit biological phenomena such as the Enhanced Permeability and Retention (EPR) effect, and to cross physiological barriers like the blood-brain barrier (BBB), has expanded the therapeutic potential of nanomedicine. Clinical success stories, including Doxil and Abraxane, underscore the translational promise of nanoparticle-based drug delivery systems.

Moreover, targeted nanocarriers have opened new avenues in oncology, enabling personalized therapy and overcoming multidrug resistance mechanisms through intracellular drug delivery and stimuli-responsive release. Advanced applications such as theranostic platforms, which integrate diagnosis and therapy within a single nanoparticle, are paving the way toward precision medicine.

Despite these advancements, challenges such as immune system interactions, long-term biocompatibility, scalability of production, and regulatory approval continue to impede widespread clinical translation. Addressing these concerns through interdisciplinary research, robust preclinical evaluation, and strategic design optimization will be essential for the next generation of nanomedicine.

In summary, nanotechnology holds immense promise for revolutionizing drug delivery systems. As research continues to evolve, nanocarrier-based therapies are expected to become increasingly central to the development of safer, more effective, and more personalized treatment modalities in modern medicine.

REFERENCES

[1] Pison U, Welte T, Giersing M, Groneberg DA: Nanomedicine for respiratory diseases. *Eu J Pharmacology* 2006, 533: 341–350. 10.1016/j.ejphar.2005.12.068
Article CAS Google Scholar

[2] Brannon-Peppase L, Blanchette JQ: Nanoparticle and targeted systems for cancer therapy. *Adv Drug Deliv Rev* 2004, 56(11):1649–1659. 10.1016/j.addr.2004.02.014
Article Google Scholar

[3] Stylios GK, Giannoudis PV, Wan T: Applications of nanotechnologies in medical practice. *Injury* 2005, 36: S6-S13. 10.1016/j.injury.2005.10.011
Article PubMed Google Scholar

[4] Yokoyama M: Drug targeting with nano-sized carrier systems. *J Artif Organs* 2005, 8(2):77–84. 10.1007/s10047-005-0285-0
Article CAS PubMed Google Scholar

[5] Schatzlein AG: Delivering cancer stem cell therapies – a role for nanomedicines? *Eur J Cancer* 2006, 42(9):1309–1315. 10.1016/j.ejca.2006.01.044
Article PubMed Google Scholar

[6] Groneberg DA, rabe KF, Fischer A: Novel concepts of neuropeptide-based therapy: Vasoactive intestinal polypeptide and its receptors. *Eu J Pharmacology* 2006, 533: 182–194. 10.1016/j.ejphar.2005.12.055
Article CAS Google Scholar

[7] Grady WM: Epigenetic events in the colorectum and in colon cancer. *Biochem Soc Trans* 2005, 33: 684–688. 10.1042/BST0330684
Article CAS PubMed Google Scholar

[8] Ould-Ouali L, Noppe M, Langlois X, Willems B, Te Riele P, Timmerman P, Brewster ME, Arien A, Preat V: Self-assembling PEG-p(CL-co-TMC) copolymers for oral delivery of poorly water-soluble drugs: a case study with

risperidone. *J Control Release* 2005, 102(3):657–668. 10.1016/j.jconrel.2004.10.022
Article CAS PubMed Google Scholar

[9] Kipp JE: The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. *Int J Pharm* 2004, 284(1–2):109–122. 10.1016/j.ijpharm.2004.07.019
Article CAS PubMed Google Scholar

[10] Fonseca C, Simoes S, Gaspar R: Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and *in vitro* anti-tumoral activity. *J Control Release* 2002, 83(2):273–286. 10.1016/S0168-3659(02)00212-2
Article CAS PubMed Google Scholar

[11] Koziara JM, Whisman TR, Tseng MT, Mumper RJ: *In-vivo* efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. *J Control Release* 2006, 112(3):312–319. 10.1016/j.jconrel.2006.03.001
Article CAS PubMed Google Scholar

[12] Yoo HS, Lee KH, Oh JE, Park TG: *In vitro* and *in vivo* anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates. *J Control Release* 2000, 68(3):419–31. 10.1016/S0168-3659(00)00280-7
Article CAS PubMed Google Scholar

[13] Bhadra D, Bhadra S, Jain S, Jain NK: A PEGylated dendritic nanoparticulate carrier of fluorouracil. *Int J Pharm* 2003, 257(1–2):111–124. 10.1016/S0378-5173(03)00132-7
Article CAS PubMed Google Scholar

[14] Panyam J, Labhasetwar V: Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles. *Mol Pharm* 2004, 1(1):77–84. 10.1021/mp034002c
Article CAS PubMed Google Scholar

[15] Koziara JM, Lockman PR, Allen DD, Mumper RJ: Paclitaxel nanoparticles for the potential treatment of brain tumors. *J Control Release* 2004, 99(2):259–269. 10.1016/j.jconrel.2004.07.006
Article CAS PubMed Google Scholar

[16] Chen AA, Derfus AM, Khetani SR, Bhatia SN: Quantum dots to monitor RNAi delivery and improve gene silencing. *Nucleic Acids Res* 2005, 33(22):e190. 10.1093/nar/gni188
Article PubMed Central PubMed Google Scholar

[17] Shinde RR, Bachmann MH, Wang Q, Kasper R, Contag CH: *PEG-PLA/PLGA Nanoparticles for In-Vivo RNAi Delivery.* NSTI Nano tech., California; 2007.
Google Scholar

[18] Tan WB, Jiang S, Zhang Y: Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. *Biomaterials* 2007, 28(8):1565–1571. 10.1016/j.biomaterials.2006.11.018
Article CAS PubMed Google Scholar

[19] Howard KA, Rahbek UL, Liu X, Damgaard CK, Glud SZ, Andersen MØ, Hovgaard MB, Schmitz A, Nyengaard JR, Besenbacher F, Kjems J: RNA interference *in vitro* and in vivo using a novel chitosan/siRNA nanoparticle system. *Mol Ther* 2006, 14(4):476–484. 10.1016/j.ymthe.2006.04.010
Article CAS PubMed Google Scholar

[20] Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, Alyautdin R: Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. *J Drug Target* 2002, 10(4):317–325. 10.1080/10611860290031877
Article CAS PubMed Google Scholar

[21] Costantino L, Gandolfi F, Tosi G, Rivasi F, Vandelli MA, Forni F: Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. *J Control Release* 2005, 108(1):84–96. 10.1016/j.jconrel.2005.07.013
Article CAS PubMed Google Scholar

[22] Sumner JP, Kopelman R: Alexa Fluor 488 as an iron sensing molecule and its application in PEBBLE nanosensors. *Analyst* 2005, 130(4):528–533. 10.1039/b414189j
Article CAS PubMed Google Scholar

[23] Michaelis K, Hoffmann MM, Dreis S, Herbert E, Alyautdin RN, Michaelis M, Kreuter J, Langer K: Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. *J Pharmacol Exp Ther* 2006, 317(3):1246–1253. 10.1124/jpet.105.097139
Article CAS PubMed Google Scholar

[24] Steiniger SC, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, Smirnova ZS, Severin SE, Uhl R, Kock M, Geiger KD, Gelperina SE: Chemotherapy of glioblastoma in rats using

doxorubicin-loaded nanoparticles. *Int J Cancer* 2004, 109(5):759–767. 10.1002/ijc.20048
Article CAS PubMed Google Scholar

[25] Zhang Y, Sun C, Kohler N, Zhang M: Self-Assembled Coatings on Individual Monodisperse Magnetite Nanoparticles for Efficient Intracellular Uptake. *Biomedical Microdevices* 2004, 6: 33–40. 10.1023/B:BMMD.0000013363.77466.63
Article CAS PubMed Google Scholar

[26] Li L, Wartchow CA, Danthi SN, Shen Z, Dechene N, Pease J, Choi HS, Doede T, Chu P, Ning S, Lee DY, Bednarski MD, Knox SJ: A Novel Antiangiogenesis Therapy Using an Integrin Antagonist or Anti-Flk-1 Antibody Coated 90Y-labeled Nanoparticles. *Int J Radiat Oncol Biol Phy* 2004, 58(4):1215–1227.
Article CAS Google Scholar

[27] Park JH, Kwon S, Nam JO, Park RW, Chung H, Seo SB, Kim IS, Kwon IC, Jeong SY: Self-assembled nanoparticles based on glycol chitosan bearing 5beta-cholanic acid for RGD peptide delivery. *J Control Release* 2004, 95(3):579–588. 10.1016/j.jconrel.2003.12.020
Article CAS PubMed Google Scholar

[28] Fenniri H, Deng BL, Ribbe AE, Hallenga K, Jacob J, Thiyagarajan P: Entropically driven self-assembly of multichannel rosette nanotubes. *Proc Nat Acad Sci* 2002, 99: 6487–6492. 10.1073/pnas.032527099
Article PubMed Central CAS PubMed Google Scholar

[29] Fenniri H, Mathivanan P, Vidale KL, Sherman DM, Hallenga K, Wood KV, Stowell JG: Helical rosette nanotubes: design, self-assembly, and characterization. *J Am Chem Soc* 2001, 123: 3854–3855. 10.1021/ja005886l
Article CAS PubMed Google Scholar

[30] Zhang D, Tan T, Gao L, Zhao W, Wang P: Preparation of azithromycin nanosuspensions by high pressure homogenization and its physicochemical characteristics studies. *Drug Dev Ind Pharm* 2007, 33(5):569–575. 10.1080/03639040600975147
Article CAS PubMed Google Scholar

[31] Gaspar R, Préat V, Opperdoes FR, Roland M: Macrophage activation by polymeric nanoparticles of polyalkylcyanoacrylates: activity against intracellular leishmania donovani associated with hydrogen peroxide production. *Pharmaceutical Research* 1992, 9(6):782–787. 10.1023/A:1015807706530
Article CAS PubMed Google Scholar

[32] Balland O, Pinto-Alphandary H, Viron A, Puvion E, Andremont A, Couvreur P: Intracellular distribution of ampiciUin in murine macrophages infected with *Salmonella typhimurium* and treated with (3H) ampicillin-loaded nanoparticles. *Journal of Antimicrobial Chemotherapy* 1996, 37: 105–115. 10.1093/jac/37.1.105
Article CAS PubMed Google Scholar

[33] Gupta S, Viyas SP: Development and characterization of amphotericin B bearing emulsomes for passive and active macrophage targeting. *J Drug Target* 2007, 15(3):206–217. 10.1080/10611860701195395
Article CAS PubMed Google Scholar

[34] Hynes RO: A reevaluation of integrins as regulators of angiogenesis. *Nat Med* 2002, 8: 918–921. 10.1038/nm0902-918
Article CAS PubMed Google Scholar

[35] Hynes RO, Zhao Q: The evolution of cell adhesion. *J Cell Biol* 2000, 24: F89-F96. 10.1083/jcb.150.2.F89
Article Google Scholar

[36] Chen X, Plasencia C, Hou Y, Neamati N: Synthesis and biological evaluation of dimeric RGD peptide-Paclitaxel conjugate as a model for integrin-targeted drug delivery. *J Med Chem* 2005, 48: 1098–1106. 10.1021/jm049165z
Article CAS PubMed Google Scholar

[37] Gupta AS, Huang G, Lestini BJ, Sagnella S, Kottke-Marchant K, Marchant RE: RGD modified liposomes targeted to activated platelets as a potential vascular drug delivery system. *Thromb Haemost* 2005, 93: 106–114.
PubMed Google Scholar

[38] Schiffelers RM, Koning GA, ten Hagen TL, Fens MH, Schraa AJ, Janssen AP, Kok RJ, Molema G, Strom G: Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. *J Control Rel* 2003, 91: 115–122. 10.1016/S0168-3659(03)00240-2
Article CAS Google Scholar

[39] Haass NK, Smalley KS, Li L, Herlyn M: Adhesion, migration and communication in melanocytes and melanoma. *Pigment Cell Res*

2005, 18: 150–159. 10.1111/j.1600-0749.2005.00235.x
Article CAS PubMed Google Scholar

[40] Christofori G: Changing neighbours, changing behaviour: Cell adhesion molecule-mediated signalling during tumour progression. *EMBO J* 2003, 22: 2318–2323. 10.1093/emboj/cdg228
Article PubMed Central CAS PubMed Google Scholar